Cargando…
Pretransplant BK Virus-Specific T-Cell-Mediated Immunity and Serotype Specific Antibodies May Have Utility in Identifying Patients at Risk of BK Virus-Associated Haemorrhagic Cystitis after Allogeneic HSCT
BK polyomavirus (BKPyV) persists lifelong in renal and urothelial cells with asymptomatic urinary shedding in healthy individuals. In some immunocompromised persons after transplantation of hematopoietic stem cells (HSCT), the BKPyV high-rate replication is associated with haemorrhagic cystitis (HC)...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625163/ https://www.ncbi.nlm.nih.gov/pubmed/34835157 http://dx.doi.org/10.3390/vaccines9111226 |
_version_ | 1784606352429023232 |
---|---|
author | Šťastná-Marková, Markéta Hamšíková, Eva Hainz, Petr Hubáček, Petr Kroutilová, Marie Kryštofová, Jitka Ludvíková, Viera Musil, Jan Pecherková, Pavla Saláková, Martina Šroller, Vojtěch Vydra, Jan Němečková, Šárka |
author_facet | Šťastná-Marková, Markéta Hamšíková, Eva Hainz, Petr Hubáček, Petr Kroutilová, Marie Kryštofová, Jitka Ludvíková, Viera Musil, Jan Pecherková, Pavla Saláková, Martina Šroller, Vojtěch Vydra, Jan Němečková, Šárka |
author_sort | Šťastná-Marková, Markéta |
collection | PubMed |
description | BK polyomavirus (BKPyV) persists lifelong in renal and urothelial cells with asymptomatic urinary shedding in healthy individuals. In some immunocompromised persons after transplantation of hematopoietic stem cells (HSCT), the BKPyV high-rate replication is associated with haemorrhagic cystitis (HC). We tested whether the status of BKPyV immunity prior to HSCT could provide evidence for the BKPyV tendency to reactivate. We have shown that measurement of pretransplant anti-BKPyV 1 and 4 IgG levels can be used to evaluate the HC risk. Patients with anti-BKPyV IgG in the range of the 1st–2nd quartile of positive values and with positive clinical risk markers have a significantly increased HC risk, in comparison to the reference group of patients with “non-reactive” anti-BKPyV IgG levels and with low clinical risk (LCR) (p = 0.0009). The predictive value of pretransplant BKPyV-specific IgG was confirmed by determination of genotypes of the shed virus. A positive predictive value was also found for pretransplant T-cell immunity to the BKPyV antigen VP1 because the magnitude of IFN-γ T-cell response inversely correlated with posttransplant DNAuria and with HC. Our novel data suggest that specific T-cells control BKPyV latency before HSCT, and in this way may influence BKPyV reactivation after HSCT. Our study has shown that prediction using a combination of clinical and immunological pretransplant risk factors can help early identification of HSCT recipients at high risk of BKPyV disease. |
format | Online Article Text |
id | pubmed-8625163 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86251632021-11-27 Pretransplant BK Virus-Specific T-Cell-Mediated Immunity and Serotype Specific Antibodies May Have Utility in Identifying Patients at Risk of BK Virus-Associated Haemorrhagic Cystitis after Allogeneic HSCT Šťastná-Marková, Markéta Hamšíková, Eva Hainz, Petr Hubáček, Petr Kroutilová, Marie Kryštofová, Jitka Ludvíková, Viera Musil, Jan Pecherková, Pavla Saláková, Martina Šroller, Vojtěch Vydra, Jan Němečková, Šárka Vaccines (Basel) Article BK polyomavirus (BKPyV) persists lifelong in renal and urothelial cells with asymptomatic urinary shedding in healthy individuals. In some immunocompromised persons after transplantation of hematopoietic stem cells (HSCT), the BKPyV high-rate replication is associated with haemorrhagic cystitis (HC). We tested whether the status of BKPyV immunity prior to HSCT could provide evidence for the BKPyV tendency to reactivate. We have shown that measurement of pretransplant anti-BKPyV 1 and 4 IgG levels can be used to evaluate the HC risk. Patients with anti-BKPyV IgG in the range of the 1st–2nd quartile of positive values and with positive clinical risk markers have a significantly increased HC risk, in comparison to the reference group of patients with “non-reactive” anti-BKPyV IgG levels and with low clinical risk (LCR) (p = 0.0009). The predictive value of pretransplant BKPyV-specific IgG was confirmed by determination of genotypes of the shed virus. A positive predictive value was also found for pretransplant T-cell immunity to the BKPyV antigen VP1 because the magnitude of IFN-γ T-cell response inversely correlated with posttransplant DNAuria and with HC. Our novel data suggest that specific T-cells control BKPyV latency before HSCT, and in this way may influence BKPyV reactivation after HSCT. Our study has shown that prediction using a combination of clinical and immunological pretransplant risk factors can help early identification of HSCT recipients at high risk of BKPyV disease. MDPI 2021-10-22 /pmc/articles/PMC8625163/ /pubmed/34835157 http://dx.doi.org/10.3390/vaccines9111226 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Šťastná-Marková, Markéta Hamšíková, Eva Hainz, Petr Hubáček, Petr Kroutilová, Marie Kryštofová, Jitka Ludvíková, Viera Musil, Jan Pecherková, Pavla Saláková, Martina Šroller, Vojtěch Vydra, Jan Němečková, Šárka Pretransplant BK Virus-Specific T-Cell-Mediated Immunity and Serotype Specific Antibodies May Have Utility in Identifying Patients at Risk of BK Virus-Associated Haemorrhagic Cystitis after Allogeneic HSCT |
title | Pretransplant BK Virus-Specific T-Cell-Mediated Immunity and Serotype Specific Antibodies May Have Utility in Identifying Patients at Risk of BK Virus-Associated Haemorrhagic Cystitis after Allogeneic HSCT |
title_full | Pretransplant BK Virus-Specific T-Cell-Mediated Immunity and Serotype Specific Antibodies May Have Utility in Identifying Patients at Risk of BK Virus-Associated Haemorrhagic Cystitis after Allogeneic HSCT |
title_fullStr | Pretransplant BK Virus-Specific T-Cell-Mediated Immunity and Serotype Specific Antibodies May Have Utility in Identifying Patients at Risk of BK Virus-Associated Haemorrhagic Cystitis after Allogeneic HSCT |
title_full_unstemmed | Pretransplant BK Virus-Specific T-Cell-Mediated Immunity and Serotype Specific Antibodies May Have Utility in Identifying Patients at Risk of BK Virus-Associated Haemorrhagic Cystitis after Allogeneic HSCT |
title_short | Pretransplant BK Virus-Specific T-Cell-Mediated Immunity and Serotype Specific Antibodies May Have Utility in Identifying Patients at Risk of BK Virus-Associated Haemorrhagic Cystitis after Allogeneic HSCT |
title_sort | pretransplant bk virus-specific t-cell-mediated immunity and serotype specific antibodies may have utility in identifying patients at risk of bk virus-associated haemorrhagic cystitis after allogeneic hsct |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625163/ https://www.ncbi.nlm.nih.gov/pubmed/34835157 http://dx.doi.org/10.3390/vaccines9111226 |
work_keys_str_mv | AT stastnamarkovamarketa pretransplantbkvirusspecifictcellmediatedimmunityandserotypespecificantibodiesmayhaveutilityinidentifyingpatientsatriskofbkvirusassociatedhaemorrhagiccystitisafterallogeneichsct AT hamsikovaeva pretransplantbkvirusspecifictcellmediatedimmunityandserotypespecificantibodiesmayhaveutilityinidentifyingpatientsatriskofbkvirusassociatedhaemorrhagiccystitisafterallogeneichsct AT hainzpetr pretransplantbkvirusspecifictcellmediatedimmunityandserotypespecificantibodiesmayhaveutilityinidentifyingpatientsatriskofbkvirusassociatedhaemorrhagiccystitisafterallogeneichsct AT hubacekpetr pretransplantbkvirusspecifictcellmediatedimmunityandserotypespecificantibodiesmayhaveutilityinidentifyingpatientsatriskofbkvirusassociatedhaemorrhagiccystitisafterallogeneichsct AT kroutilovamarie pretransplantbkvirusspecifictcellmediatedimmunityandserotypespecificantibodiesmayhaveutilityinidentifyingpatientsatriskofbkvirusassociatedhaemorrhagiccystitisafterallogeneichsct AT krystofovajitka pretransplantbkvirusspecifictcellmediatedimmunityandserotypespecificantibodiesmayhaveutilityinidentifyingpatientsatriskofbkvirusassociatedhaemorrhagiccystitisafterallogeneichsct AT ludvikovaviera pretransplantbkvirusspecifictcellmediatedimmunityandserotypespecificantibodiesmayhaveutilityinidentifyingpatientsatriskofbkvirusassociatedhaemorrhagiccystitisafterallogeneichsct AT musiljan pretransplantbkvirusspecifictcellmediatedimmunityandserotypespecificantibodiesmayhaveutilityinidentifyingpatientsatriskofbkvirusassociatedhaemorrhagiccystitisafterallogeneichsct AT pecherkovapavla pretransplantbkvirusspecifictcellmediatedimmunityandserotypespecificantibodiesmayhaveutilityinidentifyingpatientsatriskofbkvirusassociatedhaemorrhagiccystitisafterallogeneichsct AT salakovamartina pretransplantbkvirusspecifictcellmediatedimmunityandserotypespecificantibodiesmayhaveutilityinidentifyingpatientsatriskofbkvirusassociatedhaemorrhagiccystitisafterallogeneichsct AT srollervojtech pretransplantbkvirusspecifictcellmediatedimmunityandserotypespecificantibodiesmayhaveutilityinidentifyingpatientsatriskofbkvirusassociatedhaemorrhagiccystitisafterallogeneichsct AT vydrajan pretransplantbkvirusspecifictcellmediatedimmunityandserotypespecificantibodiesmayhaveutilityinidentifyingpatientsatriskofbkvirusassociatedhaemorrhagiccystitisafterallogeneichsct AT nemeckovasarka pretransplantbkvirusspecifictcellmediatedimmunityandserotypespecificantibodiesmayhaveutilityinidentifyingpatientsatriskofbkvirusassociatedhaemorrhagiccystitisafterallogeneichsct |